Herpes Virus Infections in Immunocompromised Patients: Problems and Therapeutic Interventions

References

• Bowden R, Sayers M, Fluoumoy N, et al. Cytomegalovirus immunoglobulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006–10
   PubMed Web of Science ®Google Scholar
• Ljungman P, Björkstrand B, Ehrnst A, Forsgren M, Lönnqvlst B (1991) CMV infections after autologous bone marrow transplantation (ABMT). Cytomegalovirus: Proceedings of the 3rd International symposium, Alsterdam, 1991, M P Landini. Excerpta Medica, Amsterdam, 15–18
   Google Scholar
• King S M, Petric M, Superina R, Graham N, Roberts E A. Cytomegalovirus infections in pediatric liver transplantation. Am J Dis Child 1990; 144: 1307–10
   PubMedGoogle Scholar
• Plotkln S A, Starr S, Friedman H, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991; 114: 525–31
   PubMed Web of Science ®Google Scholar
• Meyers J, Leszcynski J, Zala J, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442–6
   PubMed Web of Science ®Google Scholar
• Meyers J D. Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant 1988; 3: 95–104
   PubMed Web of Science ®Google Scholar
• O'Reilly R, Reich L, Gold J, et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: preliminary results. Transplant Proc 1983; 15: 405–11
   PubMed Web of Science ®Google Scholar
• Winston D, Ho W, Lin C, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12–18
   PubMed Web of Science ®Google Scholar
• Snydman D R. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990; 12(Suppl. 7)5839–48
   Google Scholar
• Meyers J, Reed E, Shepp D, et al. Acyclovir for prevention of CMV infection and disease after allogenic marrow transplantation. N Engl J Med 1988; 318: 70–5
   PubMed Web of Science ®Google Scholar
• Balfour H J, Chace B, Stapleton J, Simmons R, Fryd D. A randomized, placebo‐controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381–7
   PubMed Web of Science ®Google Scholar
• Goodrich J M, Bowden R A, Fisher L, Keller C, Schoch G, Meyers J D. Gancicylovir prophylaxis to prevent cytomegalovirus disease after allogenic marrow transplant. Ann Intern Med 1993; 118: 173–8
   PubMed Web of Science ®Google Scholar
• Winston D J, Ho W G, Bartonl K, Du Mond C, Ebellng D F, Buhles W C, Champlin R E. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogenic bone marrow transplant recipients. Ann Intern Med 1983; 118: 179–84
   Google Scholar
• Atkinson K, Downs K, Golenia M, Biggs J, et al. Prophylactic use of ganciclovir in allogenic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol 1991; 79: 57–62
   PubMed Web of Science ®Google Scholar
• Merlgan T C, Renlund D G, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182–6
   PubMed Web of Science ®Google Scholar
• Rlngdén O, Lönnqvlst B, Aschan J, Sundberg B. Foscarnet prophylaxis in marrow transplant recipients. Bone Marrow Transplant 1989; 4: 713
   PubMed Web of Science ®Google Scholar
• Reusser P, Gambertoglio J, Lilleby K, Meyers J. Phase I‐II trial of foscamet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473–9
   PubMed Web of Science ®Google Scholar
• Goodrich J M, Mori M, Gleaves C A, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogenic bone marrow transplantation. N Engl J Med 1991; 325: 1601–7
   PubMed Web of Science ®Google Scholar
• Schmidt G M, Horak D A, Niland J C, Duncan S R, Forman S J, Zaia J A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope‐Stanford‐Syntex CMV Study Group. N Engl J Med 1991; 324: 1005–11
   PubMed Web of Science ®Google Scholar
• Meyers J D, Ljungman P, Fisher L D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373–80
   PubMed Web of Science ®Google Scholar
• Milpied N, Harousseau J L, Moreau P, Lacroix F, Ramee J F, Billaudel S. DHPG at CMV viremia after allogenic bone marrow transplantation. Result over a four year period (1986–1990). Bone Marrow Transplant 1991; 2: 46
   Google Scholar
• Ljungman P, Aschan J, Azinge J, et al. Cytomegalovirus viremia and specific T‐helper cell responses as predictors of disease after allogeneic bone marrow transplantation. 8 J Haematol 1993; 83: 118–27
   PubMed Web of Science ®Google Scholar
• Faulds D, Heel R C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39: 597–638
   PubMed Web of Science ®Google Scholar
• Nicholson M L, Veitch P S, Donnelly P K, Flower A J, Bell P R. Treatment of renal transplant‐associated cytomegalovirus infection with ganciclovir. Transplant Proc 1990; 22: 1811–2
   PubMed Web of Science ®Google Scholar
• Rondeau E, Farquet C, Ruedin P, Fries D, Sraer J D. Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients. Transplant Proc 1990; 22: 1813–4
   PubMed Web of Science ®Google Scholar
• Smyth R L, Scott J P, Borysiewicz L K, et al. Cytomegalovirus infection in heart‐lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis 1991; 164: 1045–50
   PubMed Web of Science ®Google Scholar
• Ettinger N A, Selby P, Powles R, et al. Cytomegalovirus pneumonia: the use of ganciclovir in marrow transplant recipients. J Antimicrob Chemother 1989; 24: 53–62
   PubMed Web of Science ®Google Scholar
• Erice A, Jordan C, Chace B, Fletcher C, Chinnock B, Balfour H. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987; 257: 3082–7
   PubMed Web of Science ®Google Scholar
• Reed E, Dandliker P, Meyers J. Treatment of cytomegalovirus pneumonia with 9‐[2‐Hydroxy‐1‐(hydroxymethyl)‐ethoxymethyl]guanine and high dose corticosteroids. Ann Intern Med 1986; 105: 214–15
   PubMed Web of Science ®Google Scholar
• Shepp D, Dandliker P, Oe Miranda P, et al. Activity of 9‐[2‐Hydroxy‐1‐(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103: 368–73
   PubMed Web of Science ®Google Scholar
• Aschan J, Ringdén O, Ljungman P, Lönnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992; 24: 143–50
   PubMed Web of Science ®Google Scholar
• Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14: 831–5
   PubMed Web of Science ®Google Scholar
• Reed E C, Bowden R A, Dandliker P S, Lilleby K E, Meyers J D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783–8
   PubMed Web of Science ®Google Scholar
• Schmidt G M, Kovacs A, Zaia J A, et al. Ganciclovir/ immunoglobulin combination therapy for the treatment of human cytomegalovirus‐associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905–7
   PubMed Web of Science ®Google Scholar
• Emanuel D, Cunningham I, Jules E K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high‐dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–82
   PubMed Web of Science ®Google Scholar
• Wingard J R, Chen D Y, Burns W H, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogenic bone marrow transplantation. Blood 1988; 71: 1432–7
   PubMed Web of Science ®Google Scholar
• Reusser P, Fisher L, Buckner C, Thomas E, Meyers J. Cytomegalovirus infections after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effects of engraftment. Blood 1990; 75: 1888–94
   PubMed Web of Science ®Google Scholar
• Drew W L, Miner R C, Busch D F, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716–9
   PubMed Web of Science ®Google Scholar
• Jacobson M A, Drew W L, Feinberg J, et al. Foscarnet therapy for ganciclovir‐resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991; 163: 1348–51
   PubMed Web of Science ®Google Scholar
• Drobyski W R, Knox K K, Carrigan D R, Ash R C. Foscarnet therapy of ganciclovir‐resistant cytomegalovirus in marrow transplantation. Transplantation 1991; 52: 155–7
   PubMed Web of Science ®Google Scholar
• Stanat S C, Reardon J E, Erice A, Jordan M C, Drew W L, Biron K K. Ganciclovir‐resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991; 35: 2191–7
   PubMed Web of Science ®Google Scholar
• Tatarowicz W, Lurain N, Thompson K. A ganciclovir‐resistant clinical isolate of human cytomegalovirus exhibiting cross‐resistance to other DNA polymerase inhibitors. J Infect Dis 1992; 166: 904–7
   PubMed Web of Science ®Google Scholar
• Collins P, Larder B A, Oliver N M, Kemp S, Smith I W, Darby G. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J Gen Virol 1989; 70: 375–82
   PubMed Web of Science ®Google Scholar
• Englund J A, Zimmerman M E, Swierkosz E M, Goodman J L, Sertoli D R, Balfour H J. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990; 112: 416–22
   PubMed Web of Science ®Google Scholar
• Nugier F, Colin J N, Aymard M, Langlois M. Occurrence and characterization of acyclovir‐resistant herpes simplex virus isolates: report on a two‐year sensitivity screening survey. J Med Virol 1992; 36: 1–12
   PubMed Web of Science ®Google Scholar
• Ljungman P, Ellis M N, Hackman R C, Shepp D H, Meyers J D. Acyclovir‐resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990; 162: 244–8
   PubMed Web of Science ®Google Scholar
• Gateley A, Gander R M, Johnson P C, Kit S, Otsuka H, Kohl S. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 1990; 161: 711–5
   PubMed Web of Science ®Google Scholar
• Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir‐resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161: 1078–84
   PubMed Web of Science ®Google Scholar
• Safrin S, Crumpacker C, Chatls P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir‐resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325: 551–5
   PubMed Web of Science ®Google Scholar
• Birch C, Tyssen D, Tachedjian G, et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon‐alfa for treatment of drug‐resistant and‐sensitive herepes simplex infections. J Infect Dis 1992; 166: 108–12
   PubMed Web of Science ®Google Scholar
• Birch C, Tachedjian G, Doherty R, Hayes K, Gust I. Altered sensitivity to antiviral druts of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 1990; 162: 731–4
   PubMed Web of Science ®Google Scholar
• Ljungman P, Lönnqvist B, Ringdén O, Skinhöj P, Gahrton G. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 1989; 4: 613–5
   PubMed Web of Science ®Google Scholar
• Hoppenjans W B, Bibler M R, Orme R L, Solinger A M. Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome: see comments. Arch Dermatol 1990; 126: 1048–50
   PubMedGoogle Scholar
• Linnemann C J, Blron K K, Hoppenjans W G, Solinger A M. Emergence of acyclovir‐resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. Aids 1990; 4: 577–9
   PubMed Web of Science ®Google Scholar
• Smith K J, Kahlter D C, Davis C, James W D, Skelton H G, Angritt P. Acyclovir‐resistant varicella zoster responsive to foscarnet: letter. Arch Dermatol 1991; 127: 1069–71
   PubMed Web of Science ®Google Scholar
• Safrin S, Berger T G, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir‐resistant varicella‐zoster virus infection. Ann Intern Med 1991; 115: 19–21
   PubMed Web of Science ®Google Scholar
• Blanche S, Le Deist F, Verber F, Lenoir G, Fischer A, et al. Treatment of severe Epstein‐Barr virus‐induced polyclonal B‐lymphocyte proliferation by anti‐B‐cell monoclonal antibodies. Ann Intern Med 1988; 108: 199–203
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Suga S, Asano Y, et al. Human herpes virus‐6 infection in bone marrow transplantation. Blood 1991; 78: 1381–4
   PubMed Web of Science ®Google Scholar
• Carrigan D R, Drobyski W R, Russler S K, Tapper M A, Knox K K, Ash R C. Interstitial penumonitis associated with human herpes virus‐6 infection after marrow transplantation. Lancet 1991; 338: 147–9
   PubMed Web of Science ®Google Scholar
• Burns W H, Sandford G R. Susceptibility of human herpes virus‐6 to antivirals in vitro. J Infect Dis 1990; 162: 634–7
   PubMed Web of Science ®Google Scholar